5‑Amino‑1MQ is a selective NNMT inhibitor that the community uses off‑label to promote fat loss and improve body composition, with most users reporting positive effects. The prevailing regimen is an oral dose of about 50 mg per day, often split into two doses, and typically cycled for two to four weeks; clinician‑derived protocols echo the same daily amount. Because it has no FDA‑approved indication, all human use is off‑label or compounded, and injection‑site reactions have not emerged as a consistent concern.
Data last updated
Measured on 4 of 6 axes
Evidence shape
5-Amino-1MQ currently exists as an animal-only research compound with no published human clinical trials. The existing literature is restricted to preclinical and mechanistic studies, meaning there is no data regarding safety, efficacy, or optimal dosing in human subjects. Because no registered trials have been completed or published, the peptide lacks the foundational evidence required to support its use for any specific indication.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column · 22 out-of-stock offers not shown
How 5-AMINO-1MQ is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
The clinician practice tier reports a dose of 2.5 mg administered subcutaneously twice daily, with no specific cycling regimen described in the source.
Most users report an unspecified schedule with a typical dose around 5 mg (range 250 µg–50 mg), while a smaller group takes it daily, typically 50 mg (range 1 mg–50 mg).